Insider Selling: Natera (NASDAQ:NTRA) CEO Sells $1,090,388.25 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,725 shares of Natera stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total transaction of $1,090,388.25. Following the sale, the chief executive officer owned 123,156 shares of the company’s stock, valued at approximately $28,420,710.12. The trade was a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, February 2nd, Steven Leonard Chapman sold 85,299 shares of Natera stock. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total transaction of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The shares were sold at an average price of $238.07, for a total transaction of $1,047,508.00.

Natera Trading Up 3.0%

Shares of NTRA opened at $203.04 on Friday. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The stock has a market cap of $28.08 billion, a P/E ratio of -88.66 and a beta of 1.64. The company has a 50-day moving average of $233.31 and a two-hundred day moving average of $196.18.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. During the same period last year, the business earned ($0.26) earnings per share. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. As a group, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Guggenheim boosted their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Barclays lifted their target price on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Stephens increased their price target on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, Piper Sandler raised their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Institutional Trading of Natera

Several institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its position in shares of Natera by 47.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 3,089 shares of the medical research company’s stock worth $708,000 after buying an additional 1,000 shares during the period. Evoke Wealth LLC purchased a new position in shares of Natera in the 4th quarter worth about $415,000. Axxcess Wealth Management LLC lifted its stake in shares of Natera by 3.3% in the 4th quarter. Axxcess Wealth Management LLC now owns 4,153 shares of the medical research company’s stock valued at $951,000 after purchasing an additional 134 shares in the last quarter. Pinnbrook Capital Management LP grew its holdings in shares of Natera by 16.6% during the 4th quarter. Pinnbrook Capital Management LP now owns 41,882 shares of the medical research company’s stock worth $9,595,000 after purchasing an additional 5,968 shares during the period. Finally, Global Retirement Partners LLC increased its position in Natera by 432.0% during the 4th quarter. Global Retirement Partners LLC now owns 4,894 shares of the medical research company’s stock worth $1,121,000 after purchasing an additional 3,974 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.